A mechanical model for predicting the probability of osteoporotic hip fractures based in DXA measurements and finite element simulation

BackgroundOsteoporotic hip fractures represent major cause of disability, loss of quality of life and even mortality among the elderly population. Decisions on drug therapy are based on the assessment of risk factors for fracture, from BMD measurements. The combination of biomechanical models with clinical studies could better estimate bone strength and supporting the specialists in their decision.MethodsA model to assess the probability of fracture, based on the Damage and Fracture Mechanics has been developed, evaluating the mechanical magnitudes involved in the fracture process from clinical BMD measurements. The model is intended for simulating the degenerative process in the skeleton, with the consequent lost of bone mass and hence the decrease of its mechanical resistance which enables the fracture due to different traumatisms. Clinical studies were chosen, both in non-treatment conditions and receiving drug therapy, and fitted to specific patients according their actual BMD measures. The predictive model is applied in a FE simulation of the proximal femur. The fracture zone would be determined according loading scenario (sideway fall, impact, accidental loads, etc.), using the mechanical properties of bone obtained from the evolutionary model corresponding to the considered time.ResultsBMD evolution in untreated patients and in those under different treatments was analyzed. Evolutionary curves of fracture probability were obtained from the evolution of mechanical damage. The evolutionary curve of the untreated group of patients presented a marked increase of the fracture probability, while the curves of patients under drug treatment showed variable decreased risks, depending on the therapy type.ConclusionThe FE model allowed to obtain detailed maps of damage and fracture probability, identifying high-risk local zones at femoral neck and intertrochanteric and subtrochanteric areas, which are the typical locations of osteoporotic hip fractures.The developed model is suitable for being used in individualized cases. The model might better identify at-risk individuals in early stages of osteoporosis and might be helpful for treatment decisions.

[1]  Nico Verdonschot,et al.  Implementation of asymmetric yielding in case-specific finite element models improves the prediction of femoral fractures , 2011, Computer methods in biomechanics and biomedical engineering.

[2]  S. Cummings,et al.  A comparison of prediction models for fractures in older women: is more better? , 2009, Archives of internal medicine.

[3]  H. Amstutz,et al.  "Modes of failure" of cemented stem-type femoral components: a radiographic analysis of loosening. , 1979, Clinical orthopaedics and related research.

[4]  G. Dinant,et al.  Individualizing fracture risk prediction. , 2010, Maturitas.

[5]  Jacques P. Brown,et al.  The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women , 2007, Osteoporosis International.

[6]  B. Clarke.  Association of Hip Strength Estimates by Finite Element Analysis with Fractures in Women and Men , 2011 .

[7]  W. Leslie,et al.  Using the same bone density reference database for men and women provides a simpler estimation of fracture risk , 2010, Journal of Bone and Mineral Research.

[8]  R Pietrabissa,et al.  Finite element analysis of cancellous bone failure in the vertebral body of healthy and osteoporotic subjects , 2008, Proceedings of the Institution of Mechanical Engineers. Part H, Journal of engineering in medicine.

[9]  U Abel,et al.  Chemotherapy of advanced epithelial cancer--a critical review. , 1992, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[10]  Kozo Nakamura,et al.  Prediction of proximal femur strength using a CT-based nonlinear finite element method: differences in predicted fracture load and site with changing load and boundary conditions. , 2009, Bone.

[11]  Eve Donnelly,et al.  The assessment of fracture risk. , 2010, The Journal of bone and joint surgery. American volume.

[12]  C. Cooper,et al.  European guidance for the diagnosis and management of osteoporosis in postmenopausal women , 2008, Osteoporosis International.

[13]  D. Felsenberg,et al.  Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension , 2012, Osteoporosis International.

[14]  S. Papapoulos,et al.  A New Approach to the Development of Assessment Guidelines for Osteoporosis , 2002, Osteoporosis International.

[15]  D. Taylor.,et al.  Microcrack growth parameters for compact bone deduced from stiffness variations. , 1998, Journal of biomechanics.

[16]  R. Huiskes,et al.  Load transfer and stress shielding of the hydroxyapatite-ABG hip: a study of stem length and proximal fixation. , 2001, The Journal of arthroplasty.

[17]  A. Amis,et al.  Correlation between pre-operative periprosthetic bone density and post-operative bone loss in THA can be explained by strain-adaptive remodelling. , 1999, Journal of biomechanics.

[18]  R. Luben,et al.  Is QUS or DXA Better for Predicting the 10‐Year Absolute Risk of Fracture? , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[19]  J. Compston.  The use of combination therapy in the treatment of postmenopausal osteoporosis , 2012, Endocrine.

[20]  E. Belzile,et al.  Direct medical costs attributable to peripheral fractures in Canadian post-menopausal women , 2012, Osteoporosis International.

[21]  R. Mazess,et al.  Bone Density of the Spine and Femur in Adult White Females , 1999, Calcified Tissue International.

[22]  Jonathan J. Kaufman,et al.  A poisson process model for hip fracture risk , 2010, Medical & Biological Engineering & Computing.

[23]  R. Eastell,et al.  Six months of parathyroid Hormone (1-84) administered concurrently versus sequentially with monthly ibandronate over two years: the PTH and ibandronate combination study (PICS) randomized trial. , 2012, The Journal of clinical endocrinology and metabolism.

[24]  O. Johnell,et al.  An estimate of the worldwide prevalence and disability associated with osteoporotic fractures , 2006, Osteoporosis International.

[25]  J. Rodriguez-Portales,et al.  Ten years' experience with alendronate for osteoporosis in postmenopausal women. , 2004, The New England journal of medicine.

[26]  J. Hanson.  Standardization of Femur BMD , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[27]  Guojing Yang,et al.  The biomechanical effects of osteoporosis vertebral augmentation with cancellous bone granules or bone cement on treated and adjacent non-treated vertebral bodies: a finite element evaluation. , 2010, Clinical biomechanics.

[28]  P. C. Paris,et al.  A Critical Analysis of Crack Propagation Laws , 1963 .

[29]  A. Martínez,et al.  Epidemiology of osteoporotic hip fractures in Spain , 2006, International Orthopaedics.

[30]  Mehmet Sarikanat,et al.  Determination of bone density distribution in proximal femur by using the 3D orthotropic bone adaptation model , 2011 .

[31]  O. Johnell,et al.  FRAX™ and the assessment of fracture probability in men and women from the UK , 2008, Osteoporosis International.

[32]  Dennis M Black,et al.  Femoral Bone Strength and Its Relation to Cortical and Trabecular Changes After Treatment With PTH, Alendronate, and Their Combination as Assessed by Finite Element Analysis of Quantitative CT Scans , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[33]  L. Idolazzi,et al.  Evidence of Sustained Vertebral and Nonvertebral Antifracture Efficacy with Ibandronate Therapy: A Systematic Review , 2011, Therapeutic advances in musculoskeletal disease.

[34]  M. Reiser,et al.  Prediction of the fracture load of whole proximal femur specimens by topological analysis of the mineral distribution in DXA-scan images. , 2008, Bone.

[35]  W. Hayes,et al.  The compressive behavior of bone as a two-phase porous structure. , 1977, The Journal of bone and joint surgery. American volume.

[36]  J. Bilezikian,et al.  Combination anabolic and antiresorptive therapy for osteoporosis. , 2012, Endocrinology and metabolism clinics of North America.

[37]  C. Cooper,et al.  Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis , 2010, Therapeutics and clinical risk management.

[38]  C. Kovacs,et al.  Predicting fracture using 2D finite element modelling. , 2012, Medical engineering & physics.

[39]  Luis Gracia,et al.  Long-term study of bone remodelling after femoral stem: a comparison between dexa and finite element simulation. , 2007, Journal of biomechanics.

[40]  J. Sliney,et al.  Combination therapy with risedronate and teriparatide in male osteoporosis , 2013, Endocrine.

[41]  B. Clarke,et al.  Effect of Recombinant Human Parathyroid Hormone (1-84) on Vertebral Fracture and Bone Mineral Density in Postmenopausal Women with Osteoporosis: A Randomized Trial , 2008 .

[42]  H. Hagino.  [Epidemiology of osteoporotic fractures]. , 2003, Clinical calcium.

[43]  Prasanth B. Nair,et al.  Use of a statistical model of the whole femur in a large scale, multi-model study of femoral neck fracture risk. , 2009, Journal of biomechanics.

[44]  N. Michailidis,et al.  Fracture risk in the femoral hip region: A finite element analysis supported experimental approach. , 2012, Journal of biomechanics.

[45]  M. Nevitt,et al.  Active Shape Modeling of the Hip in the Prediction of Incident Hip Fracture , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[46]  P. Chabrand,et al.  Femoral neck fracture prediction by anisotropic yield criteria , 2009 .

[47]  L. Rubenstein,et al.  Risk-adjusted mortality rates of elderly veterans with hip fractures. , 2007, Annals of epidemiology.

[48]  B. Abrahamsen,et al.  Safety of bisphosphonates. , 2011, Bone.

[49]  C. Christiansen,et al.  Ibandronate: A Comparison of Oral Daily Dosing Versus Intermittent Dosing in Postmenopausal Osteoporosis , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.